الولايات المتحدة · منصات وبيانات · Yahoo Finance

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

نشره Yahoo Finance · الولايات المتحدة منذ 9 س

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential…

اقرأ المقال كاملًا على Yahoo Finance سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finance.yahoo.com)

يستحق القراءة أيضًا

The Motley Fool

Is It Too Late to Buy Energy Transfer After a 25% Rally? History Has a Clear Answer.

MarketBeat

NORMA Group Unveils New Strategy Targeting 10%+ EBIT Margin by 2031

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stocktwits